Saroglitazar was also found effective in lowering ALT [17, 18, 22] and improving fatty liver (evaluated by sonographic (FibroScanTM) investigation) in NAFLD patients with diabetic dyslipidemia [18]. The gene discussed is GPT; the disease is fatty liver disease.